NASDAQ:FULC • US3596161097
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FULCRUM THERAPEUTICS INC (FULC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-12 | JP Morgan | Initiate | Overweight |
| 2025-12-11 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-09 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-12-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-12-08 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-12-08 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-12-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-30 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-10-30 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-10-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-30 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-07-29 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-05-29 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-23 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-05-15 | Cantor Fitzgerald | Upgrade | Neutral -> Overweight |
| 2025-02-26 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-14 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-09-13 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-09-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-09-12 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-09-12 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-09-12 | Stifel | Downgrade | Buy -> Hold |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.34M -66.91% | 2.805M -55.76% | 80M 2,752.05% | -100.00% | 40.529M | 145.76M 259.64% | 238.86M 63.87% | 318.07M 33.16% | 407.25M 28.04% | 479.58M 17.76% | |||
| EBITDA YoY % growth | -109.72M -39.72% | -108.492M 1.12% | -18.241M 83.19% | -84.093M -357.10% | -105.531M -26.57% | -138.25M -31.00% | -149.733M -8.31% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -112.13M -38.35% | -110.664M 1.31% | -19.834M 82.08% | -86.072M -327.39% | -102.625M -21.06% | -121.399M -18.29% | -106.091M 12.61% | -3.547M 96.66% | 81.941M 2,409.95% | 153.07M 86.81% | 233.55M 52.58% | 297.2M 27.25% | |
| Operating Margin | -1,768.61% | -3,945.24% | -24.79% | N/A | N/A | N/A | -261.77% | -2.43% | 34.31% | 48.12% | 57.35% | 61.97% | |
| EPS YoY % growth | -2.48 -8.30% | -1.58 36.29% | -0.22 86.08% | -1.20 -436.36% | -1.31 -10.72% | -1.60 -22.73% | -1.03 35.96% | 0.02 101.99% | 1.02 4,912.50% | 1.89 85.04% | 2.63 39.08% | 3.24 22.97% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.30 -7.30% | -0.32 -12.93% | -0.33 -7.35% | -0.31 -1.45% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -22.738M -10.08% | -24.568M -28.51% | -31.086M -49.34% | N/A |
| EBIT Q2Q % growth | -23.48M -26.21% | -24.504M -23.66% | -25.428M -16.33% | -25.295M -11.47% |
All data in USD
16 analysts have analysed FULC and the average price target is 19.38 USD. This implies a price increase of 186.26% is expected in the next year compared to the current price of 6.77.
FULCRUM THERAPEUTICS INC (FULC) will report earnings on 2026-04-29.
The consensus EPS estimate for the next earnings of FULCRUM THERAPEUTICS INC (FULC) is -0.3 USD and the consensus revenue estimate is 0 USD.